Pegasys/Copegus combo pack clears FDA
Executive Summary
Roche will continue to sell Pegasys (peginterferon alpha-2a) and Copegus (ribavirin) separately following FDA's June 4 approval of a co-packaged version. Roche is not announcing a launch date or pricing information for the combination. Availability of a co-packaged product could lessen the likelihood that patients will combine Pegasys with generic equivalents to Schering-Plough's Rebetol (ribavirin) (1"The Pink Sheet" April 12, 2004, p. 38)...